#USA #Tampa #Avalon Healthcare #Diagnostic Intelligence #Lab Trend Report

Avalon 2026 Lab Trend Report: A Call for Enhanced Diagnostic Management

In the realm of healthcare, laboratory testing plays a pivotal role, influencing almost 70% of clinical decisions. However, despite its significance, diagnostic spending continues to outstrip actual utilization as seen in Avalon Healthcare Solutions’ latest report called the `2026 Lab Trend Report`. The report, which analyzes the behavior of over 37 million health plan members, sheds light on the pressing need for strategic improvements in managing diagnostic services.

Current Landscape of Diagnostic Spending

The report points out that laboratory diagnostics, though recognized as the most frequently utilized medical benefits, are not managed effectively. With diagnostic spend climbing faster than its use in both routine and genetic testing, there is an emergent requirement for evidence-based methods that can enhance affordability while still prioritizing quality care. As Bill Kerr, CEO of Avalon Healthcare Solutions, states, "Diagnostics are no longer simply supporting healthcare — they're shaping it."

The Major Opportunities in Routine Testing

Routine laboratory tests constitute about 90% of all diagnostic evaluations. They serve as a core facet of disease discovery, diagnosis, and ongoing management. However, even small increases in spending can compound due to factors such as service sites, inflationary pricing, and broader test panels. In 2025, routine testing expenditure rose by 3.7% despite a mere 0.5% uptick in usage, indicating that the costs are driven less by the number of tests and more by elevated prices at various testing venues. Projections suggest that spending on routine tests will continue to expand by 5-7% annually over the next decade.

Price Disparities Across Testing Locations

One consistent finding in the report is the considerable variances in laboratory costs based on testing locations. Hospital outpatient laboratories charge significantly more—1.5 to 6.8 times higher than independent labs—for identical tests. For instance, comprehensive metabolic panels are almost seven times more expensive at hospital labs compared to independent ones, notwithstanding the absence of superior quality. Such discrepancies reveal a substantial opportunity for health plans to reduce costs via improved management of laboratory services and optimizing testing locations.

Genetic Testing as a Rapidly Evolving Sector

On the flip side, genetic testing represents the quickest-growing and most intricate sector of laboratory diagnostics. The report reveals a startling 35% increase in spending on genetic testing in 2025, alongside a 22% rise in utilization, driven by advancements in precision medicine, oncology, reproductive health testing, and rare disease diagnostics. Currently, genetic tests account for about 15% of laboratory utilization but dominate over 30% of laboratory costs.

Members receiving genetic tests incurred an average annual expenditure of $1,504 per person, significantly surpassing the $490 spent on routine tests. With approximately 10 new genetic tests entering the U.S. market daily and over 175,000 genetic tests available commercially, this rapid innovation presents new hurdles for management strategies. Forecasts project continued vigorous growth in genetic testing expenditures, ranging from 14-21% in the next 5 to 8 years.

Delivering Results Through Evidence-Based Management

Avalon aims to aid payers and providers in effective testing management to optimize costs while ensuring appropriate access to diagnostic services. In 2025, Avalon’s methodologies helped clients avert costs of $63.1 million through Routine Test Management and another $70.3 million via Genetic Test Management, leading to a total avoidance of over $133 million in laboratory expenses. This equates to 15.5% of total laboratory spending, alongside an anticipated 10-15% long-term change in provider behavior due to policy management.

Key Trends Shaping Future Diagnostics

Additionally, the report identifies three critical forces expected to reshape the landscape of laboratory medicine:

• - The advent of AI-enabled diagnostics alongside evolving regulatory frameworks
• - The rise of next-generation blood biomarkers, notably in multi-cancer early detection and Alzheimer’s disease testing
• - The surge in consumer-generated diagnostic data propelled by direct-to-consumer testing and wearable technologies

These findings emphasize the necessity for a shift from conventional management strategies towards a more sophisticated Diagnostic Intelligence approach that fuses scientific evidence, clinical proficiency, and real-time data to uplift quality, reduce costs, and enhance patient outcomes.

For those seeking comprehensive insights, the complete `2026 Avalon Lab Trend Report` and its accompanying infographic can be accessed at Avalon Healthcare Resources.

• ---

About Avalon Healthcare Solutions

Avalon stands as a leader in the domain of diagnostic intelligence, dedicated to empowering health plans and providers to fully leverage the value of diagnostic science. Their comprehensive solutions aim to expedite the implementation of actionable innovations and maximize diagnostic investments. By employing their proprietary Diagnostic Insights Platform, Avalon integrates evidence-based strategies, curated laboratory networks, and actionable insights, ultimately enhancing health outcomes and reducing costs. To learn more about Avalon, please visit Avalon Healthcare Solutions.